search
Back to results

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL)

Primary Purpose

Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity

Status
Active
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
Nebivolol
Placebo
Sponsored by
Giulio Stefanini
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Breast Cancer focused on measuring anthracycline chemotherapy, nebivolol, cardio-oncology, cancer therapy-related cardiovascular toxicity, cardiac magnetic resonance, primary prevention, cardioprotection, cardiotoxicity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥18 years Established histologic diagnosis of breast cancer or diffuse large B-cell lymphoma Planned chemotherapy with anthracyclines left ventricular ejection fraction ≥55% (assessed by echocardiography) Ability to provide informed consent Exclusion Criteria: Known intolerance/contraindications to betablocker therapy History of coronary artery disease History of cardiomyopathy History of heart failure Ongoing treatment with betablockers for other indications Heart rate at baseline <60 beats per minute Arterial blood pressure at baseline <100/60 mmHg Contraindications to undergo cardiac magnetic resonance (e.g., non-compatible pacemakers or metallic prosthesis) Pregnancy or lactation Current participation to another study

Sites / Locations

  • IRCCS Humanitas Research Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Nebivolol

Placebo

Arm Description

nebivolol, capsule, 5 mg once daily, for 12 months

placebo, capsule, once daily, for 12 months

Outcomes

Primary Outcome Measures

Left Ventricular Ejection Fraction reduction assessed by Cardiac Magnetic Resonance
The primary endpoint is defined as Left Ventricular Ejection Fraction (LVEF) reduction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12 months of follow-up. LVEF reduction is defined as the difference between LVEF at baseline and LVEF at 12 months follow-up (LVEF reduction = Baseline LVEF - 12 months LVEF).

Secondary Outcome Measures

Left ventricular ejection fraction assessed by Cardiac Magnetic Resonance
Left ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12-month follow-up.
Myocardial fibrosis assessed by Cardiac Magnetic Resonance
Myocardial fibrosis assessed by Cardiac Magnetic Resonance with T1-mapping sequences and with Late Gadolinium Enhancement images.
Myocardial edema assessed by Cardiac Magnetic Resonance
Myocardial edema assessed by Cardiac Magnetic Resonance with T2 sequences.
Right ventricular ejection fraction assessed by Cardiac Magnetic Resonance
Right ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance
Left ventricular end-diastolic volume assessed by Cardiac Magnetic Resonance
Left ventricular end-diastolic volume (unit of measurement: ml) assessed by Cardiac Magnetic Resonance
Left ventricular end-systolic volume assessed by Cardiac Magnetic Resonance
Left ventricular end-systolic volume (unit of measurement: ml) assessed by Cardiac Magnetic Resonance
Left ventricular mass assessed by Cardiac Magnetic Resonance
Left ventricular mass (unit of measurement: g/m²) assessed by Cardiac Magnetic Resonance
Left ventricular ejection fraction assessed by Echocardiography
Left ventricular ejection fraction (unit of measurement: %) assessed by Echocardiography
Left ventricular diastolic function assessed by Echocardiography
Left ventricular diastolic function assessed by Echocardiography according to Guidelines of European Association of Cardiovascular Imaging / American Society of Echocardiography
Right ventricular systolic function assessed by Echocardiography
Right ventricular systolic function assessed by Echocardiography according to Guidelines of European Association of Cardiovascular Imaging / American Society of Echocardiography
Left ventricular end-diastolic volume assessed by Echocardiography
Left ventricular end-diastolic volume (unit of measurement: ml) assessed by Echocardiography
Left ventricular end-systolic volume assessed by Echocardiography
Left ventricular end-systolic volume (unit of measurement: ml) assessed by Echocardiography
Serum troponin
Serum high-sensitivity cardiac troponin I levels (unit of measurement: ng/L)
Serum B-type natriuretic peptide (BNP)
Serum B-type natriuretic peptide (BNP) (unit of measurement: pg/mL)
Serum N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP)
Serum N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) levels (unit of measurement: pg/mL)
All-cause mortality
All-cause mortality
Cardiovascular mortality
Cardiovascular mortality or death will be defined as any death due to immediate cardiovascular cause (e.g. myocardial infarction, low-output failure, arrhythmia). Unwitnessed death and death of unknown cause will be classified as cardiac death.
Myocardial infarction
Myocardial infarction will be defined according to the 3rd Universal Definition.
Cerebrovascular events
Cerebrovascular events will be defined as follows: Transient ischemic attack: rapidly developed clinical signs of global disturbance of cerebral function lasting fewer <24 hours, regardless of the presence of an acute clinically relevant brain lesion in imaging. Ischemic stroke: rapidly developed clinical signs of focal or global disturbance of cerebral function lasting >24 hours with imaging of an acute clinically relevant brain lesion. Intracerebral haemorrhage: diagnosis must be confirmed by cerebral imaging.
Hospitalization for heart failure
Hospitalization for heart failure will be defined as any unplanned hospital readmission due to signs and symptoms of heart failure.

Full Information

First Posted
January 25, 2023
Last Updated
February 21, 2023
Sponsor
Giulio Stefanini
Collaborators
Agenzia Italiana del Farmaco
search

1. Study Identification

Unique Protocol Identification Number
NCT05728632
Brief Title
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
Acronym
CONTROL
Official Title
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
February 28, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Giulio Stefanini
Collaborators
Agenzia Italiana del Farmaco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised. So far, the evidence supporting pharmacological preventive strategies in cardio-oncology has been inconsistent and conflicting, and there is a clear need for well-designed trials with novel interventions. In this study, by using cardiac magnetic resonance, the investigators want to assess if a commonly used beta-blocker with a unique pharmacological profile, i.e. nebivolol, can prevent cardiac dysfunction in patients with breast cancer or diffuse large B-cell lymphoma undergoing chemotherapy with anthracyclines.
Detailed Description
During the last decades, major efforts have been made in the field of cancer therapy to improve prognosis and quality of life of patients treated with any sort of chemotherapy. Cardiotoxicity represents one of the most relevant adverse effects of chemotherapy, primarily in patients treated with anthracyclines. The potential protective role of cardiovascular medications in the prevention of cardiotoxicity associated with anthracyclines chemotherapy is still a matter of debate since evidence in this field are scarce and largely inconclusive. Indeed, prior studies were often limited by a non-blinded design or an echocardiography-based assessment of left ventricular ejection fraction (with a relevant inter and intra-operator variability). The primary objective of the trial is to evaluate the cardioprotective effects of the betablocker nebivolol in an individually randomized, parallel, placebo-controlled, double-blinded (patient, treating physician, investigator, outcomes assessor, statistician), superiority trial in patients with a solid tumor (i.e., breast cancer) or a hematologic malignancy (i.e., diffuse large B cell lymphoma) who have a normal cardiac function as assessed by echocardiography and will receive anthracyclines as part of their first-line chemotherapy program. Indeed, recent evidence suggests that anthracycline cardiotoxicity seems mainly due to an anthracycline-induced dysregulation of mitochondrial activity and metabolism in cardiomyocytes. Nebivolol has a distinctive profile among beta-blockers, with the unique power of increasing the nitric oxide bioavailability. Nebivolol-induced nitric oxide release has shown favourable effects in terms of antioxidant activity, cardiac neo-angiogenesis, mitochondrial and endothelial protection. On this basis, the individually randomized, parallel, placebo-controlled, double-blinded (patient, treating physician, investigator, outcomes assessor, statistician), superiority CONTROL trial will assess the cardioprotective effects of a commonly used betablocker (nebivolol) in patients with baseline normal left ventricular systolic function receiving anthracycline chemotherapy as first-line chemotherapy for breast cancer or diffuse large B-cell lymphoma. The assessment of left ventricular ejection fraction and related endpoints will be performed with cardiac magnetic resonance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction, Chemotherapy Effect
Keywords
anthracycline chemotherapy, nebivolol, cardio-oncology, cancer therapy-related cardiovascular toxicity, cardiac magnetic resonance, primary prevention, cardioprotection, cardiotoxicity

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomized 1:1 to two groups in parallel for the duration of the study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Patients, treating physicians, investigators, and outcome assessors are masked to the allocated treatment.
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nebivolol
Arm Type
Experimental
Arm Description
nebivolol, capsule, 5 mg once daily, for 12 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
placebo, capsule, once daily, for 12 months
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Other Intervention Name(s)
Lobivon
Intervention Description
Nebivolol, capsule, 5 mg once daily, for 12 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo, capsule, once daily, for 12 months
Primary Outcome Measure Information:
Title
Left Ventricular Ejection Fraction reduction assessed by Cardiac Magnetic Resonance
Description
The primary endpoint is defined as Left Ventricular Ejection Fraction (LVEF) reduction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12 months of follow-up. LVEF reduction is defined as the difference between LVEF at baseline and LVEF at 12 months follow-up (LVEF reduction = Baseline LVEF - 12 months LVEF).
Time Frame
from baseline to 12 months
Secondary Outcome Measure Information:
Title
Left ventricular ejection fraction assessed by Cardiac Magnetic Resonance
Description
Left ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12-month follow-up.
Time Frame
at 12-month follow-up
Title
Myocardial fibrosis assessed by Cardiac Magnetic Resonance
Description
Myocardial fibrosis assessed by Cardiac Magnetic Resonance with T1-mapping sequences and with Late Gadolinium Enhancement images.
Time Frame
at 12-month follow-up
Title
Myocardial edema assessed by Cardiac Magnetic Resonance
Description
Myocardial edema assessed by Cardiac Magnetic Resonance with T2 sequences.
Time Frame
at 12-month follow-up
Title
Right ventricular ejection fraction assessed by Cardiac Magnetic Resonance
Description
Right ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance
Time Frame
at 12-month follow-up
Title
Left ventricular end-diastolic volume assessed by Cardiac Magnetic Resonance
Description
Left ventricular end-diastolic volume (unit of measurement: ml) assessed by Cardiac Magnetic Resonance
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular end-systolic volume assessed by Cardiac Magnetic Resonance
Description
Left ventricular end-systolic volume (unit of measurement: ml) assessed by Cardiac Magnetic Resonance
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular mass assessed by Cardiac Magnetic Resonance
Description
Left ventricular mass (unit of measurement: g/m²) assessed by Cardiac Magnetic Resonance
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular ejection fraction assessed by Echocardiography
Description
Left ventricular ejection fraction (unit of measurement: %) assessed by Echocardiography
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular diastolic function assessed by Echocardiography
Description
Left ventricular diastolic function assessed by Echocardiography according to Guidelines of European Association of Cardiovascular Imaging / American Society of Echocardiography
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Right ventricular systolic function assessed by Echocardiography
Description
Right ventricular systolic function assessed by Echocardiography according to Guidelines of European Association of Cardiovascular Imaging / American Society of Echocardiography
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular end-diastolic volume assessed by Echocardiography
Description
Left ventricular end-diastolic volume (unit of measurement: ml) assessed by Echocardiography
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Left ventricular end-systolic volume assessed by Echocardiography
Description
Left ventricular end-systolic volume (unit of measurement: ml) assessed by Echocardiography
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Serum troponin
Description
Serum high-sensitivity cardiac troponin I levels (unit of measurement: ng/L)
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Serum B-type natriuretic peptide (BNP)
Description
Serum B-type natriuretic peptide (BNP) (unit of measurement: pg/mL)
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
Serum N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP)
Description
Serum N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) levels (unit of measurement: pg/mL)
Time Frame
at different timepoints (1-month, 6-month, 12-months)
Title
All-cause mortality
Description
All-cause mortality
Time Frame
at 12-month follow-up
Title
Cardiovascular mortality
Description
Cardiovascular mortality or death will be defined as any death due to immediate cardiovascular cause (e.g. myocardial infarction, low-output failure, arrhythmia). Unwitnessed death and death of unknown cause will be classified as cardiac death.
Time Frame
at 12-month follow-up
Title
Myocardial infarction
Description
Myocardial infarction will be defined according to the 3rd Universal Definition.
Time Frame
at 12-month follow-up
Title
Cerebrovascular events
Description
Cerebrovascular events will be defined as follows: Transient ischemic attack: rapidly developed clinical signs of global disturbance of cerebral function lasting fewer <24 hours, regardless of the presence of an acute clinically relevant brain lesion in imaging. Ischemic stroke: rapidly developed clinical signs of focal or global disturbance of cerebral function lasting >24 hours with imaging of an acute clinically relevant brain lesion. Intracerebral haemorrhage: diagnosis must be confirmed by cerebral imaging.
Time Frame
at 12-month follow-up
Title
Hospitalization for heart failure
Description
Hospitalization for heart failure will be defined as any unplanned hospital readmission due to signs and symptoms of heart failure.
Time Frame
at 12-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years Established histologic diagnosis of breast cancer or diffuse large B-cell lymphoma Planned chemotherapy with anthracyclines left ventricular ejection fraction ≥55% (assessed by echocardiography) Ability to provide informed consent Exclusion Criteria: Known intolerance/contraindications to betablocker therapy History of coronary artery disease History of cardiomyopathy History of heart failure Ongoing treatment with betablockers for other indications Heart rate at baseline <60 beats per minute Arterial blood pressure at baseline <100/60 mmHg Contraindications to undergo cardiac magnetic resonance (e.g., non-compatible pacemakers or metallic prosthesis) Pregnancy or lactation Current participation to another study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gianluigi Condorelli, MD,PhD,Prof
Organizational Affiliation
IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Giulio G Stefanini, MD,PhD,Prof
Organizational Affiliation
IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carmelo Carlo-Stella, MD,Prof
Organizational Affiliation
IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
IRCCS Humanitas Research Hospital
City
Rozzano
State/Province
Milan
ZIP/Postal Code
20089
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines

We'll reach out to this number within 24 hrs